Rhythm Pharmaceuticals (NASDAQ:RYTM) is a biopharmaceutical company focused on developing treatments for rare genetic obesity disorders. The company has gained attention for its innovative approach, particularly with its drug setmelanotide, which targets the melanocortin-4 receptor (MC4R). This focus has positioned Rhythm as a leader in the rare genetic obesity market, as noted by RBC Capital Markets.
On March 3, 2026, Dennis Ding from Jefferies set a price target of $125 for NASDAQ:RYTM, suggesting a potential upside of 39.57% from its current trading price of $89.56. Jefferies reiterated a Buy rating, showing confidence in the company's future performance. This optimism is supported by Rhythm's recent success in a Phase 3 trial for hypothalamic obesity, which significantly boosted its market capitalization by $3.5 billion.
RBC Capital Markets has also recognized Rhythm's leadership in the rare genetic obesity market. Analyst Lisa Walter highlighted the company's success in the Phase 3 TRANSCEND trial, which evaluated setmelanotide for treating hypothalamic obesity. The trial achieved its primary endpoint, showing a -19.8% placebo-adjusted difference in BMI reduction, which is both statistically significant and clinically meaningful.
The stock for NASDAQ:RYTM is currently priced at $89.56, reflecting a decrease of 5.67% or $5.38. Despite this recent dip, the stock has shown significant volatility, with a trading range between $87.21 and $92.75 yesterday. Over the past year, RYTM has reached a high of $122.20 and a low of $45.91, indicating substantial fluctuations in its market performance.
Rhythm Pharmaceuticals' market capitalization is approximately $5.98 billion, with a trading volume of 1,524,813 shares on the NASDAQ exchange. The company's strong market position and recent trial successes contribute to the positive outlook from analysts like Jefferies and RBC Capital Markets, who see potential for further growth in the rare obesity treatment market.
